Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ Jr
GLP-1s are not going anywhere pharma manufacturers continue to evolve their GLP-1/GIP product offerings (e.g., Eli Lillys Zepbound is the newest on the market), and the number of addressable indications is increasing (e.g., recent clinical evidence that may merit further FDA approval of GLP-1s for cardio-metabolic, nephrological and neurological indications)
Given the potential adverse consequences of sarcopenic obesity there is a need to educate healthcare professionals about the risks and to incorporate lifestyle interventions to prevent gains in fat and optimise muscle mass following GLP-1 RA cessation
All of the mice were housed under standard laboratory conditions (12 h12 h onoff
This method provides high sensitivity and specificity, ensuring the purity and quality of therapeutic peptides for pharmaceutical use
Cancer results from the abnormal development of cells